Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss

Obesity

Volumn 15, Issue 4, 2007, Pages 895-905

  Erondu, Ngozi ^a   Wadden, Thomas ^b   Gantz, Ira ^a   Musser, Bret ^a   Nguyen, Allison Martin ^a   Bays, Harold ^c   Bray, George ^d   O'Neil, Patrick M ^e   Basdevant, Arnaud ^f   Kaufman, Keith D ^a   Heymsfield, Steven B ^a   Amatruda, John M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^d PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f HÔTEL DIEU   (France)

Author keywords

Diet; Neurochemistry; Neuropeptide Y; Neurotransmitter; Weight maintenance

Indexed keywords

EID: 34248342673     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2007.620     Document Type: Article

References (45)

1. National Task Force on the Prevention and Treatment of Obesity, National Institutes of Health. Very low-calorie diets. JAMA. 1993;270:967-74.
2. Wadden TA, Berkowitz RI. Very low calorie diets. In: Fairburn CG, Brownell KD, eds. Eating Disorders and Obesity: A Comprehensive Handbook. 2nd ed. New York: Guilford Press; 2002, pp. 534-38.
3. Wadden TA, Stunkard AJ. Controlled trial of very low calorie diet, behavior therapy, and their combination in the treatment of obesity. J Consult Clin Psychol. 1986;54:482-8.
4. Wadden TA, Sternberg JA, Letizia KA, Stunkard AJ, Foster GD. Treatment of obesity by very low calorie diet, behavior therapy, and their combination: a five-year perspective. Int J Obes Relat Metab Disord. 1989;13(Suppl 2):39S-46S.
5. Finer N, Finer S, Naoumova RP. Drug therapy after very-low-calorie diets. Am J Clin Nutr. 1992;56(Suppl 1):195S-8S.
6. Andersen T, Astrup A, Quaade F. Dexfenfluramine as adjuvant to a low-calorie formula diet in the treatment of obesity: a randomized clinical trial. Int J Obes Relat Metab Disord. 1992;16:35-40.
7. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med. 1999;106:179-84.
8. Mathus-Vliegen EM, Balance Study Group. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study. Eur J Clin Nutr. 2005;59(Suppl 1):S31-8.
9. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature. 2000;404:661-71.
10. Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, Kalra PS. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev. 1999;20:68-100.
11. Schwartz MW, Sipols AJ, Marks JL, et al. Inhibition of hypothalamic neuropeptide Y gene expression by insulin. Endocrinology. 1992;130:3608-16.
12. Stephens TW, Basinski M, Bristow PK, et al. The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature. 1995;377:530-2.
13. Baskin DG, Breininger JF, Schwartz MW. Leptin receptor mRNA identifies a subpopulation of neuropeptide Y neurons activated by fasting in rat hypothalamus. Diabetes. 1999;48:828-33.
14. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature. 2002;418:650-4.
15. Willesen MG, Kristensen P, Romer J. Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat. Neuroendocrinology. 1999;70:306-16.
16. Dickson SL, Luckman SM. Induction of c-fos messenger ribonucleic acid in neuropeptide Y and growth hormone (GH)-releasing factor neurons in the rat arcuate nucleus following systemic injection of the GH secretagogue, GH-releasing peptide-6. Endocrinology. 1997;138:771-7.
17. Kumarnsit E, Johnstone LE, Leng. Actions of neuropeptide Y and growth hormone secretagogues in the arcuate nucleus and ventromedial hypothalamic nucleus. Eur J Neurosci. 2003;17:937-44.
18. Lynch RM, Tompkins LS, Brooks HL, Dunn-Meynell AA, Levin BE. Localization of glucokinase gene expression in the rat brain. Diabetes. 2000;49:693-700.
19. Lam TK, Schwartz GJ, Rossetti L. Hypothalamic sensing of fatty acids. Nat Neurosci. 2005;8:579-84.
20. Gerald C, Walker MW, Criscione L, et al. A receptor subtype involved in neuropeptide-Y-induced food intake. Nature. 1996;382:168-71.
21. Hu Y, Bloomquist BT, Cornfield LJ, et al. Identification of a novel hypothalamic neuropeptide Y receptor associated with feeding behavior. J Biol Chem. 1996;271:26315-9.
22. Sawchenko PE. Toward a new neurobiology of energy balance, appetite, and obesity: the anatomists weigh in. J Comp Neurol. 1998;402:435-41.
23. Elias CF, Saper CB, Maratos-Flier E, et al. Chemically defined projections linking the mediobasal hypothalamus and the lateral hypothalamic area. J Comp Neurol. 1998;402:442-59.
24. Cowley MA, Pronchuk N, Fan W, Dinulescu DM, Colmers WF, Cone RD. Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraventricular nucleus: evidence of a cellular basis for the adipostat. Neuron. 1999;24:155-63.
25. Kishi T, Aschkenasi CJ, Choi BJ, et al. Neuropeptide Y Y1 receptor mRNA in rodent brain: distribution and colocalization with melanocortin-4 receptor. J Comp Neurol. 2005;482:217-43.
26. Cabrele C, Langer M, Bader R, et al. The first selective agonist for the neuropeptide YY5 receptor increases food intake in rats. J Biol Chem. 2000;275:36043-8.
27. Mullins D, Kirby D, Hwa J, Guzzi M, Rivier J, Parker E. Identification of potent and selective neuropeptide Y Y(1) receptor agonists with orexigenic activity in vivo. Mol Pharmacol. 2001;60:534-40.
28. Parker EM, Balasubramaniam A, Guzzi M, et al. [D-Trp(34)] neuropeptide Y is a potent and selective neuropeptide Y Y(5) receptor agonist with dramatic effects on food intake. Peptides. 2000;21:393-9.
29. Kanatani A, Mashiko S, Murai N, et al. Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice. Endocrinology. 2000;141:1011-6.
30. Turnbull AV, Ellershaw L, Masters DJ, et al. Selective antagonism of the NPY Y5 receptor does not have a major effect on feeding in rats. Diabetes. 2002;51:2441-9.
31. Kanatani A, Ishihara A, Iwaasa H, MacNeil DJ, Fukami T. Development of NPY antagonists and their anorectic effects. Folia Pharmacol Japonica. 2006;127:88-91.
32. Erondu N, Gantz I, Musser B, et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese Adults. Cell Metab. 2006;4:275-82.
33. James WP, Avenell A, Broom J. Whitehead J. A one-year trial to assess the value of orlistat in the management of obesity. Int J Obes Relat Metab Disord. 1997;21(Suppl 3):S24-30.
34. Kolotkin RL, Head S, Hamilton M, Tse CK. Assessing impact of weight on quality of life. Obes Res. 1995;3:49-56.
35. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-83.
36. The EuroQol Group. EuroQol: a new facility for the measurement of health related quality of life. Health Policy. 1990;16:199.
37. Gadbury GL, Coffey CS, Allison DB. Modern statistical methods for handling missing repeated measurements in obesity trial data: beyond LOCF. Obes Rev. 2003;4:175-84.
38. Peto R. Clinical trial methodology. Biomedicine. 1978;28:24-36.
39. Hill Jo, Hauptman J, Anderson JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr. 1999;69:1108-16.
40. Pedrazzini T, Seydoux J, Kunstner P, et al. Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nat Med. 1998;4:722-6.
41. Kushi A, Sasai H, Koizumi H, Takeda N, Yokoyama M, Nakamura M. Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice. Proc Natl Acad Sci U S A. 1998;95:15659-64.
42. Marsh DJ, Hollopeter G, Kafer KE, Palmiter RD. Role of the Y5 neuropeptide Y receptor in feeding and obesity. Nat Med. 1998;4:718-21.
43. Anderson JW, Konz EC, Frederich RC, Wood CL. Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr. 2001;74:579-84.
44. Saris WH. Very-low-calorie diets and sustained weight loss. Obes Res. 2001;9(Suppl):295S-301S.
45. Wadden TA, Foster GD, Letizia KA. One-year behavioral treatment of obesity: Comparison of moderate and severe caloric restriction and the effects of weight maintenance therapy. J Consult Clin Psychol. 1994;62:165-171.